KEI Statement at WTO COVID-19 Vaccine Equity Event

On Wednesday April 14, 2021, the World Trade Organization hosted an event titled “COVID-19 and Vaccine Equity: What can the WTO contribute?” which featured three sessions concerning vaccine distribution, manufacturing, and looking forward at how the system could better address… Continue Reading

Fissures on intellectual property, C-TAP and transparency emerge in WHO local production negotiations

On 4 December 2020, Ethiopia submitted a Zero Draft resolution to the World Health Organization (WHO) on Strengthening Local Production of Medicines and Other Health Technologies to Improve Access – WHO Resolution on Strengthening Local Production of Medicines and Other… Continue Reading

License to NIH Spike Protein Technology Needed in COVID-19 Vaccines Demonstrates “Available to the Public on Reasonable Terms” Requirement

A March 21, 2021 New York Times article on vaccine access discusses how a technology invented and owned by the National Institutes of Health (NIH) is necessary to make several COVID-19 vaccines. The invention mentioned by the Times, titled Prefusion… Continue Reading

Luis Gil Abinader NIST comments on the definition of Subject Invention, 26 March 2021

PDF version here:LGA-NIST-Subject-Invention-definition-26March2021 More on the NIST proposed changes to the Bayh-Dole Regulations. https://www.keionline.org/35432 Comments of Luis Gil Abinader of Knowledge Ecology International on the redefinition of “Subject Invention” to Narrow the Inventions to Which Government Rights Attach (Modify 37… Continue Reading

On Joe Allen’s claims that former Senators can provide authoritative statements on legislative intent decades after leaving office, especially when they worked as lobbyists

A recent blog published in IPWatchdog expresses outrage at accurate observations made by James Love, director of Knowledge Ecology International (KEI), that former Senators Birch Bayh and Bob Dole acquired financial ties to the pharmaceutical industry between the enactment of… Continue Reading

Canada based Biolyse Pharma Seeks to Manufacture COVID-19 Vaccines for Low-Income Countries, may test Canada’s compulsory licensing for export law

On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading

Hungarian compulsory license for remdesivir raises a stir with BIO, PhRMA and the US Chamber of Commerce

Whilst TRIPS Council deliberations in 2020 witnessed some lively deliberations on the nature of legislative amendments to Hungary’ special legal order (State of Danger) to enable the provision of a “compulsory licence regime for public health purposes”, Hungary’s recent decision… Continue Reading